

Unaudited Interim Condensed Consolidated Financial Statements of MOUNTAIN VALLEY MD HOLDINGS INC.

For the three and nine months ended December 31, 2021 and 2020

Interim Condensed Consolidated Statements of Financial Position (Unaudited, in thousands of Canadian Dollars)

	Note		ember 31, 2021	N	March 31, 2021
Current Assets Cash and cash equivalents HST recoverable Prepaids, deposits and other Note receivable Right of use asset	3	\$	15,293 285 802 111 56 16,547	\$	19,510 236 1,138 107 86 21,077
Long-term Assets Intangible assets Equity investments Investment in associate Capital assets	4 5		4,575 3,820 27 242 8,664		4,769 5,384 89 289 10,531
		\$	25,211	\$	31,608
TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY					
Current Liabilities Accounts payable and accrued liabilities Deferred revenue Lease liability		\$	272 250 28 550	\$	776 250 40 1,066
Long-term Liabilities Lease liability			26 576		44 1,110
Shareholders' Equity Share capital Class B shares Contributed surplus Warrants Deficit	6 6 6		52,173 2,399 3,712 3,152 (36,801) 24,635	\$	51,706 2,399 1,006 3,152 (27,765) 30,498

Approved on behalf of the Board:

/s/ "Dennis Hancock" /s/ "Kevin Puloski"

MOUNTAIN VALLEY MD HOLDINGS INC.
Interim Condensed Consolidated Statements of Loss
(Unaudited, in thousands of Canadian Dollars, except for per share amounts)

	For the three month		th period ended,	For the nine month	e nine month period ended,	
	Note	December 31, 2021	December 31, 2020	December 31, 2021	December 31, 2020	
Expenses General and administrative Research and development	7	1,011 242	449 -	3,182 1,201	1,491 -	
Stock based compensation	7	682	28	2,729	56	
Amortization of intangible assets Depreciation of capital assets and right-of use	4	87	85	260	252	
assets		26	17	77	53	
		2,048	579	7,449	1,852	
Net loss before other items		2,048	579	7,449	1,852	
Other items Loss from sale of assets Loss from equity accounted associates Fair value loss on equity investments Accretion and interest on convertible debt Investment income and other Interest earned on note receivable	5	- 20 1,111 - (10) (1)	455 177 - - - (1)	- 62 1,564 - (35) (4)	455 266 253 20 (4) (4)	
		1,120	631	1,587	986	
Net loss for the period		3,168	1,210	9,036	2,838	
Basic and diluted loss per share		\$ (0.01)	\$ (0.00)	\$ (0.03) \$	\$ (0.01)	
Weighted average number of shares outstanding		329,412,049	252,831,065	329, 123, 937	252, 151,427	

MOUNTAIN VALLEY MD HOLDINGS INC.
Interim Condensed Consolidated Statements of Changes in Equity
(Unaudited, in thousands of Canadian Dollars, except for per share amounts)

	Class B	Class B						_	
	Non-voting Number of Shares	Non-voting Share Capital		Common Shares Share capital	Subscriptions received	Contributed surplus	Warrants	To Deficit	otal Shareholders' Equity
		\$		\$	\$	\$	\$	\$	\$
Balance at March 31, 2020 (restated)	50,056,229	2,399	243,691,267	25,962	_	442	1,887	(19,622)	11,068
Shares issued for debt	-	-,	8,357,185	433	-	-	-	-	433
Exercise of stock options	-	-	2,100,000	107	-	-	-	-	107
Issuance of stock options	-	-	-	-		56	-	-	56
Conversion of convertible note	-	-	875,000	350	-	(120)	-	-	230
Shares issued for finder's fees	-	-	250,000	41	-	-	-	-	41
Shares for services	-	-	912,500	73	-	-	-	-	73
Shares issued for private placement	-	-	19,650,908	4,323	-	-	-	-	4,323
Shares issued as finders fees for private		_	1,107,436	244					244
placement	-	-	1,107,430	244	-	-	-	-	244
Share issue costs	-	-	-	(298)	-	-	44	-	(254)
Exercise of warrants	-	-	3,518,570	1,232	82	-	-	-	1,314
Net loss for the period	-	-	-	-		-	-	(2,838)	(2,838)
Balance at December 31, 2020 (restated)	50,056,229	2,399	280,462,866	32,467	82	378	1,931	(22,460)	14,797
Balance at March 31, 2021	50,056,229	2,399	327,837,591	51,706	_	1,006	3,152	(27,765)	30,498
Exercise of stock options	-	-	600,000	68	_	(23)	-	-	45
Issuance of stock options	-	-	· -	-	_	2,729	_	-	2,729
Shares for services	-	-	258,958	49	_	_	_	-	49
Exercise of warrants	-	-	885,000	350	-	-	-	-	350
Net loss for the period	-	-		-	-	-	-	(9,036)	(9,036)
Balance at December 31, 2021	50,056,229	2,399	329,581,549	52,173	-	3,712	3,152	(36,801)	24,635

Interim Condensed Consolidated Statements of Cash flows (Unaudited, in thousands of Canadian Dollars)

For the nine month period ended, December 31.

		Dece	cember 31,		
	Note	2021		2020	
OPERATING ACTIVITIES					
Net loss for the period	\$	(9,036)	\$	(2,838)	
Adjustments for:					
Common shares issued for consulting services		50		-	
Accretion on convertible debt		-		3	
Fair value loss on equity investments	5	1,564		253	
Loss from equity accounted associates		62		133	
Stock based compensation	7	2,729		56	
Amortization of intangible assets	4	260		252	
Depreciation of capital assets and right-of use assets		77		53	
Loss from sale of assets				455	
Interest earned on convertible note		(4)		(4)	
miles out carried on convention rete		χ-1			
		(4,298)		(1,637)	
Changes in non-cash operating working capital		(4,250)		(1,001)	
HST receivable		(50)		(117)	
Prepaid expenses and deposits		336		185	
		330		98	
Shareholder loan repayment		(524)			
Accounts payable		(534)		(36)	
Net cash used in operating activities:		(4,546)		(1,507)	
Net cash used in operating activities.		(4,540)		(1,507)	
INVESTING ACTIVITIES					
		(66)		(277)	
Cash paid to acquire intellectual property Legal fees to maintain licenses	4	(66)		(277)	
		•		(15)	
Capital asset additions		<u>-</u>		(249)	
Niek anderson die immersking nekisiking					
Net cash used in investing activities:		(66)		(541)	
FINANCING ACTIVITIES					
Cash received from sale of subsidiary		-		436	
Subscriptions received		-		82	
Issuance of share capital, net of issue costs		-		4,312	
Exercise of stock options	6	45		107	
Exercise of warrants	6	350		1,232	
Net cash received from financing activities:		395		6,169	
Net change in cash		(4,217)		4,121	
Cash and cash equivalents - Beginning of period		19,510		1,742	
Cash and cash equivalents - End of period	\$	15,293	\$	5,863	
Castrana castregarvarents - Ena or perioa	Ψ	10,230	Ψ	5,005	

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

1. NATURE OF OPERATIONS

Mountain Valley MD Holdings Inc. (the "Company"), was incorporated under the provisions of the British Columbia Business Corporations Act on March 8, 2005. The Company is a publicly traded health and wellness company engaged, through its wholly owned subsidiary Mountain Valley MD Inc, in building a world-class organization centered around the implementation and licensing of its key technologies to global pharmaceutical, vaccine and nutraceutical third parties.

The Company's common shares trade on the Canadian Securities Exchange under the ticker symbol "MVMD" and on the OTCQB under the ticker symbol "MVMDF".

The address of the Company's principal place of business is 260 Edgeley Boulevard, Unit 4, Concord, Ontario, Canada, L4K 3Y4.

2. BASIS OF PRESENTATION

a) Statement of compliance

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").

The Company's board of directors approved the release of these interim condensed consolidated financial statements on February 28, 2022.

b) Basis of measurement

In preparing its interim condensed consolidated financial statements, the Company makes judgments in applying its accounting policies. The judgments that have the most significant effect on the amounts recognized in the consolidated financial statements are outlined below in section c). In addition, the preparation of consolidated financial statements in conformity with IFRS requires the use of estimates that affect the amounts reported and disclosed in the consolidated financial statements and related notes. These estimates are based on management's best knowledge of the relevant facts and circumstances, having regard to previous experience, but actual results may differ materially from the amounts included in the interim condensed consolidated financial statements. Information about assumptions and other sources of estimation uncertainty as at December 31, 2021 that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year are outlined below in section c).

c) Areas of judgment and estimation uncertainty

The preparation of the consolidated financial statements in conformity with IFRS requires the use of judgments and/or estimates that affect the amounts reported and disclosed in the consolidated financial statements and related notes. These judgments and estimates are based on management's best knowledge of the relevant facts and circumstances, having regard to previous experience, but actual results may differ materially from the amounts included in the consolidated financial statements.

In preparation of the interim condensed consolidated financial statements, the significant estimates and judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended March 31, 2021.

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

3. PREPAID EXPENSES AND OTHER ASSETS

	December 31, 2021	March 31, 2021
	\$	\$
Prepaid	501	296
Research and development trials	-	780
Supplies inventory	243	45
Formulation inventory	40	-
Lease deposits	18	17
	802	1,138

4. INTANGIBLE ASSETS

The Company's intellectual property consists of the following:

	\$
Cost	
As at March 31, 2021	5,159
Additions	66
As at December 31, 2021	5,225
Accumulated amortization	
As at March 31, 2021	390
Depreciation expense	260
As at December 31, 2021	650
Carrying amounts:	
As at December 31, 2021	4,575
As at March 31, 2021	4,769

- a) The Company recorded additions of \$66 during the nine-month period ended December 31, 2021 related to direct costs to acquire new patents.
- b) The Company recorded \$260 of depreciation expense during the nine-month period ended December 31, 2021 based on the estimated useful life of the portfolio of patents.

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

5. EQUITY INVESTMENTS

The following summarizes the Company's investments at December 31, 2021:

	March 31, 2021	Additions	Unrealized Gains / (Losses)	December 31, 2021
	\$	\$	\$	(
Sixth Wave Innovations Inc. (a)	137	-	(71)	66
Palisade Goldcorp Ltd. (b)	3,196	_	(1,375)	1,821
Nevada King Gold Corp. (b)	1,721	223	(489)	1,455
Mexican Gold Mining Corp. (b)	-	22	(4)	18
Radio Fuels Energy Corp. (b)	-	143	(13)	130
Circadian Wellness Corp. (c)	330	-	_	330
	5,384	388	(1,952)	3,820

a) Sixth Wave Innovations Inc.

On October 1, 2019, Mountain Valley MD Inc. subscribed for 333,333 ordinary shares of Sixth Wave Innovations Inc. (CSE: SIXW) by way of private placement for a subscription price of \$250.

As at December 31, 2021, management re-valued the investment to \$66 (March 31, 2021: \$137) based on Level 1 input under the IFRS 13 fair value hierarchy using the trading price of Sixth Wave Innovations Inc. as at December 31, 2021.

b) <u>Nevada King Gold Corp., Palisade Goldcorp Ltd., Mexican Gold Mining Corp., and Radio Fuels</u> Energy Corp.

On November 18, 2019, the Company disposed of its shares of Desert Hawk Resources Inc. to Casino Gold Corp. Casino Gold Corp. issued 10,000,000 shares to the Company which represented approximately 5.8% of Casino Gold's issued and outstanding shares.

In January 2020, Casino Gold Corp completed a plan of arrangement in which Casino Gold Corp. was split into two private companies. On October 14, 2021, Palisades Goldcorp Ltd. completed a plan of arrangement to distribute equity shares to shareholders of Palisades Goldcorp Ltd. The Company now owns the following equity investments:

- 4,042,738 common shares of Nevada King Gold Corp. (formerly Nevada King Mining Ltd, and formerly 1234721 B.C. Ltd.)
- 799,000 common shares of Palisade Goldcorp Ltd.
- 443,147 common shares of Mexican Gold Mining Corp.
- 326,339 common shares of Radio Fuels Energy Corp.

As at December 31, 2021, management fair valued Palisade Goldcorp Ltd. using Level 2 inputs under the IFRS 13 fair value hierarchy. The fair value was based on the most recent private sale by Palisade Goldcorp Ltd. The fair value of the investment in Palisade Goldcorp has been reduced by the fair value of the distributed equity shares noted in the above paragraph.

As at December 31, 2021, management fair valued Nevada King Gold Corp., Mexican Gold Mining Corp., and Radio Fuels Energy Corp., based on Level 1 inputs under the IFRS 13 fair value hierarchy (December 31, 2020, Level 2 inputs). The fair value was determined using the market trading price as at December 31, 2021.

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

.... Note 5. EQUITY INVESTMENTS (Continued)

Prior to the amalgamation (Note 6), shareholders of the Company (formerly, Meadow Bay Gold Corporation) received one additional Class B share of the Company for each common share held.

The special rights and restrictions of the Class B shares provide that if:

- the Company decides, by way of a director's resolution to distribute the Casino Gold shares (now Palisade Goldcorp Ltd., Nevada King Gold Corp., Mexican Gold Mining Corp., and Radio Fuels Energy Corp.); or
- the Company completes the sale of all or any portion of the Casino Gold shares,

the Company will redeem all of the outstanding Class B shares for an amount equal to the redemption price.

Since the Company has discretion over any distribution or disposal that would require a redemption of the Class B shares, the above special rights and restrictions do not result in a liability classification. The Class B shares have therefore been presented as equity.

c) Circadian Wellness Corp.

The Company owns 1,222,222 shares (post 3:1 share split on May 27, 2021) of Circadian Wellness Corp. a private Ontario corporation focusing on mushroom farming, extraction, clinical research and development, and end-user consumer health and wellness products and retreats.

The Company has reviewed the fair value of this equity investment in light of relevant information available and determined that the valuation as at December 31, 2021 has not changed from the initial subscription price.

6. SHARE CAPITAL

a) Share Capital

Authorized

The Company has authorized share capital of:

- Unlimited Common Shares without par value.
- 50,056,229 Class B Non-Voting shares (Note 5(b))

Issued and outstanding

The Company has issued share capital of 329,581,549 Common Shares and 50,056,229 Non-Voting Class B shares.

Share issuances during the nine months ended December 31, 2021

The Company issued 600,000 shares in regard to the exercise of stock options. The Company received \$45 in gross proceeds.

The Company issued 885,000 shares in regard to the exercise of warrants. The Company received \$350 in gross proceeds.

The Company issued 258,958 shares with a fair value of \$49 for consulting services.

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

.... Note 6. SHARE CAPITAL (Continued)

The continuity of the Company's stock options is as follows:

		Weighted Average
	Outstanding	Exercise
	Options	Price
		\$
March 31, 2020	13,499,438	0.11
Issued	4,210,000	1.360
Forfeited	(400,000)	
Expired	(410,938)	
Excercised	(4,100,000)	0.05
Balance at March 31, 2021	12,798,500	0.49
Issued	4,770,000	0.29
Exercised	(600,000)	0.07
Forfeited	(50,000)	1.45
Balance at December 31, 2021	16,918,500	0.44

The following table summarizes the stock options outstanding at December 31, 2021:

		Weighted	
		Average	
		Exercise	Options
Expiry Date	Number	Price	exercisable
March 13, 2025	3,785,000	0.07	3,785,000
May 1, 2025	250,000	0.075	250,000
May 3, 2025	4,288,500	0.05	4,288,500
August 20, 2025	100,000	0.22	100,000
December 1, 2025	135,000	0.095	135,000
December 14, 2025	1,000,000	0.29	1,000,000
February 12, 2026	2,590,000	2.04	1,295,000
July 14, 2026	3,690,000	0.27	738,000
August 1, 2026	1,000,000	0.365	200,000
December 13, 2026	80,000	0.135	16,000
	16,918,500	0.44	11,807,500

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

.... Note 6. SHARE CAPITAL (Continued)

b) Warrants

The continuity of the Company's share purchase warrants is as follows:

		Weighted Average	Weighted Average
	Outstanding	Remaining	Exercise
	Warrants	Life (Years)	Price
			\$
March 31, 2020	51,875,028	1.37	0.38
Issued	14,562,763	1.76	0.38
Exercised	(48,879,052)		0.35
Expired	(1,047,861)		0.55
March 31, 2021	16,510,878	1.56	0.44
Exercised	(885,000)	-	0.35
Expired	(595,968)	_	1.72
Balance at December 31, 2021	15,029,910	0.89	0.39

The following table summarizes the share purchase warrants outstanding at December 31, 2021:

		Weighted Average Exercise
Expiry Date	Number Number	Price
January 4, 2022	902,147	0.60
July 11, 2023	875,000	0.48
December 18, 2022	3,273,593	0.13
December 21, 2022	9,979,170	0.45
	15,029,910	0.39

7. RELATED PARTY TRANSACTIONS

Key management includes personnel having the authority and responsibility for planning, directing and controlling the Company and includes the directors and executive officers.

Salaries, consulting fees, and benefits incurred to key management are:

	Nine months ended	Nine months ended
	December 31, 2021	December 31, 2020
	\$	\$
Face and because	207	0.40
Fees and benefits	397	348
Stock based compensation	1,634	38
	2,031	386

There are \$Nil amounts included in accounts payable and accrued liabilities as at December 31, 2021 and March 31, 2021 owing to key management.

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

8. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company's financial instruments include cash and cash equivalents, note receivable, equity investments, accounts payable and accrued liabilities, and lease liability. The carrying amounts of these financial instruments are a reasonable estimate of their fair values based on their current nature and current market rates for similar financial instruments.

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of inputs used to estimate the fair values. The three levels of the fair value hierarchy are

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability

either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

As at December 31, 2021, the Company did not have any financial assets and liabilities which are measured at fair value, other than equity investments. There were no transfers between Level 1, 2 or 3 during the ninemonth period ended December 31, 2021.

a) Credit risk

Credit risk is the risk that the financial benefits of contracts with a specific counterparty will be lost if a counterparty defaults on its obligations under the contract. Credit risk arises from cash and note receivable. The amount of credit risk related to cash and cash equivalents is considered insignificant as the Company's funds are held with a large Canadian bank. The Company obtains financial information from the creditor to determine the carrying amount of the note receivable.

The credit risk for both the cash and cash equivalent and note receivable is monitored quarterly, and any change is reflected as an adjustment through expected credit loss.

b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure. The Company monitors and reviews current and future cash requirements and matches the maturity profile of financial assets and liabilities.

As at December 31, 2021, the Company's financial liabilities have contractual maturities as summarized below:

	Due within		
	0-12 months	1-2 years	2-3 years
	\$	\$	\$
Accounts payable and accrued liabilities	272	-	_
Lease liability	28	26	
Total	300	26	

c) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices and is comprised of currency risk, interest rate risk, and other price risk.

Sensitivity analysis

The Company has completed a sensitivity analysis to estimate the impact on comprehensive earnings which a change in the market price of equity investments would have on the Company during the nine-month period ended December 31, 2021. As a result, a 10% change in the equity investments will translate to a \$382 gain or loss from equity investments.

:

Notes to the Interim Condensed Consolidated Financial Statements Nine months ended December 31, 2021 and December 31, 2020 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

9. SEGMENT INFORMATION

Management has determined that the Company has one reportable operating segment, being research and development of its delivery, solubility, and adjuvant technologies. This segment accounts for all of the Company's operating expenses. Determination of the operating segment was based on the level of financial reporting to the Company's chief decision makers.

All of the Company's fixed assets are located in Canada. The Company has investments in associates (Note 5) and cannabis licenses that are located in Colombia. These licenses have been fully written down in prior periods.

10. CAPITAL MANAGEMENT

The Company manages its cash, common shares, warrants and share purchase options as capital. The Company's objectives when managing capital are to safeguard its ability to continue as a going concern and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, acquire or dispose of assets or adjust the amount of cash held.

11. SUBSEQUENT EVENTS

On January 24, 2022, 902,147 share purchase warrants with an exercise price of \$0.60 expired unexercised.

On January 25, 2022, the Company granted 2,525,000 share purchase options exercisable at \$0.22 per share for five years to various Company officers, directors and consultants.

On January 25, 2022, the Company granted 875,000 restricted share units for nil proceeds to various Company directors, officers and consultants, which may vest, in whole or in part, subject to the satisfaction of certain performance measures, to be settled upon vesting by way of cash payment or issuance of common shares of the Company at the discretion of the Company.

On February 1, 2022, the Company cancelled 2,590,000 share purchase options exercisable at \$2.04 per share to various Company officers, directors and consultants. These share purchase options were originally granted on February 12, 2021 and had a five-year expiry date.